No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.


BRCA & HBOC
Toggle Menu

Tumor Testing

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

Related Force Information

Medicare Establishes National Coverage Policy for Next Generation Sequencing for Tumors
Blog post about Medicare's decision to cover FDA-approved or FDA-cleared tumor tests for people with advanced or metastatic cancer.

Tumor gene test may determine which breast cancer patients can forgo chemotherapy
XRAYS article which looks at research on whether MammaPrint, a test that looks at 70 genes in breast cancer tumors, can reliably determine which patients should get chemotherapy, focusing on women who were determined to be at high risk for breast cancer recurrence using a program that takes into account many clinical factors.

TRITON3: Tumor Testing and PARP Inhibitor Study in Metastatic Prostate Cancer
Information from our clinical trial matching tool on a study enrolling patients with metastatic castration-resistant prostate cancer who have either an inherited or somatic mutation that may indicate sensitivity to the PARP inhibitor rucaparib. This study includes tumor testing to see which tumors may respond best to this treatment.

A cancer patient’s tumor is genetically profiled—how does that info help her treatment?
XRAYS article about Jessica Wapner's Scientific American article exploring the difficulties of making the vast amount of information acquired from tumor gene tests useful to patients and physicians.

Medicare Establishes National Policy for Coverage of Tumor Testing
The Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) to provide Medicare beneficiaries with coverage of FDA-approved or -cleared companion diagnostic tests. The new policy applies specifically to patients with advanced cancer.

Newly developed tumor test may identify more BRCA-like breast cancers
XRAYS article about development of HRDetect, a test that looks at tumor tissue to determine whether a breast cancer tumor has similar features to breast cancers in people with an inherited BRCA mutation.

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)
Information from our clinical trial matching tool on a study enrolling patients with metastatic castration-resistant prostate cancer who have either an inherited or somatic mutation that may indicate sensitivity to the PARP inhibitor rucaparib. This study includes tumor testing to see which tumors may respond best to this treatment.

Can MammaPrint guide treatment decisions?
XRAYS article about the American Society of Clinical Oncology (ASCO) updating its guidelines for MammaPrint, a genomic tumor test that guides treatment decisions for patients with early-stage invasive breast cancer based on the results of a large study.

Predicting which women have breast cancers that will respond to hormone therapy alone
XRAYS article on research on Oncotype DX Recurrence Score test, a test that identifies the level of gene activity in breast tumors, can show which breast cancer patients are candidates for hormone therapy alone, without chemotherapy.

FORCE:Facing Our Risk of Cancer Empowered